NO972930L - Fibronectin-adhesjonsinhibitorer - Google Patents
Fibronectin-adhesjonsinhibitorerInfo
- Publication number
- NO972930L NO972930L NO972930A NO972930A NO972930L NO 972930 L NO972930 L NO 972930L NO 972930 A NO972930 A NO 972930A NO 972930 A NO972930 A NO 972930A NO 972930 L NO972930 L NO 972930L
- Authority
- NO
- Norway
- Prior art keywords
- amino acid
- acid selected
- fibronectin
- terminus
- linker
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 3
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 2
- 150000008575 L-amino acids Chemical class 0.000 abstract 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 2
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 150000001576 beta-amino acids Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det beskrives cykliske peptider med formel (1) >-.AA1-AA2-AA3-AA'^ LINKER' (1) hvor AA1 er en L- eller ^-aminosyre valgt fra Ile ogLeu eller en aminosyreanalog derav, AA2 er en L-aminosyre valgl fra Lau eller en aminosyreanalog derav, AA3 er en L-aminosyre valgt fra Asp eller en aminosyreanalog cderav, som i sin sidekjede inneholderen karboksylgruppe; AA4 er en L-aminosyre valgt fra Val eller en aminosyreanalog derav, og; LINKER representerer en sammenkoblende del for å koble N-enden av AA1 til C- enden av AA4 under dannelse av et cyklisk peptid som inneholder en heterocyklisk ring som har 17 til 30 ledd. De cykliske peptidene inhiberer interaksjonen mellom VCAM-1 (Vascular Cell Adhesion Molecule-1) og fibronectin, med integrinet VLA-4 (Very Late Antigen 4) og har terapeutiske anvendelser, f eks. ved reumatoid artritt eller multippel sklerose.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9426254.0A GB9426254D0 (en) | 1994-12-24 | 1994-12-24 | Chemical compounds |
| GBGB9505905.1A GB9505905D0 (en) | 1995-03-23 | 1995-03-23 | Methods |
| GBGB9513904.4A GB9513904D0 (en) | 1995-07-07 | 1995-07-07 | Chemical compounds |
| PCT/GB1995/002992 WO1996020216A1 (en) | 1994-12-24 | 1995-12-21 | Fibronectin adhesion inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO972930D0 NO972930D0 (no) | 1997-06-23 |
| NO972930L true NO972930L (no) | 1997-08-19 |
Family
ID=27267539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO972930A NO972930L (no) | 1994-12-24 | 1997-06-23 | Fibronectin-adhesjonsinhibitorer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6034056A (no) |
| EP (1) | EP0800535A1 (no) |
| JP (1) | JP3248584B2 (no) |
| CN (1) | CN1171118A (no) |
| AU (1) | AU705717B2 (no) |
| BR (1) | BR9510284A (no) |
| CA (1) | CA2204793A1 (no) |
| CZ (1) | CZ198497A3 (no) |
| GB (1) | GB9524630D0 (no) |
| HU (1) | HUT77120A (no) |
| IL (1) | IL116512A0 (no) |
| MX (1) | MX9704767A (no) |
| NO (1) | NO972930L (no) |
| NZ (1) | NZ297530A (no) |
| PL (1) | PL320995A1 (no) |
| SK (1) | SK81097A3 (no) |
| TR (1) | TR199501656A2 (no) |
| WO (1) | WO1996020216A1 (no) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0842195A1 (en) * | 1995-07-06 | 1998-05-20 | Zeneca Limited | Peptide inhibitors of fibronectine |
| GB9613112D0 (en) * | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| PL323130A1 (en) * | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
| DE19653036A1 (de) * | 1996-12-19 | 1998-06-25 | Merck Patent Gmbh | Cyclopeptidderivate |
| US6291511B1 (en) | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
| US6221888B1 (en) | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
| US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US6069163A (en) * | 1997-10-21 | 2000-05-30 | Merck & Co., Inc. | Azapeptide acids as cell adhesion inhibitors |
| US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| US6090841A (en) * | 1997-11-21 | 2000-07-18 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EP1242118B1 (en) | 1999-12-16 | 2009-11-11 | Biogen Idec MA Inc. | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| NZ518886A (en) | 1999-12-28 | 2004-02-27 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| GB0015923D0 (en) * | 2000-06-30 | 2000-08-23 | Astrazeneca Ab | Methods |
| DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EP1423400B2 (en) * | 2001-03-19 | 2013-05-22 | President and Fellows of Harvard College | Evolving new molecular function |
| DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
| EP1423135A4 (en) * | 2001-08-06 | 2006-06-07 | Univ California | PROCESS FOR INHIBITING THE ANGIOGENESIS |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| US7247725B2 (en) | 2002-10-30 | 2007-07-24 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
| CA2545248A1 (en) | 2003-09-29 | 2005-04-14 | The Regents Of The University Of California | Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| SE0302853D0 (sv) * | 2003-10-29 | 2003-10-29 | Astrazeneca Ab | Chemical compounds |
| EP1734966B1 (en) | 2004-04-13 | 2013-07-31 | Incyte Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| MEP1008A (xx) | 2005-12-21 | 2010-02-10 | Incyte Corp | 3-aminociklopentankarboksamidi kao modulatori receptora hemokina |
| WO2007092471A2 (en) | 2006-02-03 | 2007-08-16 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
| CA2714335A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| FR2914304B1 (fr) * | 2007-03-28 | 2012-11-16 | Guerbet Sa | Composes pour le diagnostic de maladies liees a l'expression de vcam. |
| JP2012502927A (ja) | 2008-09-22 | 2012-02-02 | メルク カナダ インコーポレイテッド | Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体 |
| WO2010051274A2 (en) * | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| GEP20146064B (en) | 2008-11-26 | 2014-03-25 | Pfizer | 3-minocyclopentanecarboxamides as chemokine receptor modulators |
| TW201041892A (en) | 2009-02-09 | 2010-12-01 | Supergen Inc | Pyrrolopyrimidinyl Axl kinase inhibitors |
| MY152062A (en) | 2009-02-24 | 2014-08-15 | Merck Sharp & Dohme | Indole derivatives as crth2 receptor antagonists |
| WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| US8853149B2 (en) | 2010-03-19 | 2014-10-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Integrin interaction inhibitors for the treatment of cancer |
| WO2012051036A1 (en) | 2010-10-11 | 2012-04-19 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| ES2635030T3 (es) | 2010-12-23 | 2017-10-02 | Merck Sharp & Dohme Corp. | Quinoxalinas y aza-quinoxalinas como moduladores del receptor CRTH2 |
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| CA2831392C (en) | 2011-03-28 | 2020-04-28 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| WO2012151137A1 (en) | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| ES2613644T3 (es) | 2011-06-17 | 2017-05-25 | Merck Sharp & Dohme Corp. | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores del receptor CRTH2 |
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| EA032088B1 (ru) | 2011-10-27 | 2019-04-30 | Массачусетс Инститьют Оф Текнолоджи | Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство |
| CA2884870C (en) | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| GB201400292D0 (en) | 2014-01-08 | 2014-02-26 | Haemostatix Ltd | Peptide dendrimers and agents |
| CN106659731A (zh) | 2014-05-30 | 2017-05-10 | 夏尔人类遗传性治疗公司 | 用于递送核酸的可生物降解脂质 |
| MX2017000143A (es) | 2014-06-24 | 2017-05-01 | Shire Human Genetic Therapies | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos. |
| WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| EP3247378B8 (en) | 2015-01-09 | 2023-08-23 | Revolution Medicines, Inc. | Macrocyclic compounds that participate in cooperative binding and medical uses thereof |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| HUE062274T2 (hu) | 2015-06-19 | 2023-10-28 | Massachusetts Inst Technology | Alkenil-szubsztituált 2,5-piperazindionok és alkalmazásuk hatóanyag alanyba vagy sejtbe történõ célbajuttatására szolgáló készítményekben |
| CA3000822A1 (en) | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| WO2017079820A1 (en) * | 2015-11-11 | 2017-05-18 | Encycle Therapeutics, Inc. | CYCLIC PEPTIDES TARGETING α4β7 INTEGRIN |
| EP3442599B1 (en) | 2016-04-12 | 2022-03-30 | Warp Drive Bio, Inc. | Compositions and methods for the production of compounds |
| CA3042231A1 (en) | 2016-10-28 | 2018-05-03 | Ginkgo Bioworks, Inc. | Compositions and methods for the production of compounds |
| CA3042576A1 (en) * | 2016-11-11 | 2018-05-17 | Encycle Therapeutics, Inc. | Cyclic peptides multimers targeting .alpha.4.beta.7 integrin |
| WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
| CA3062385A1 (en) | 2017-05-10 | 2018-11-15 | Encycle Therapeutics, Inc. | Homodetic cyclic peptides targeting a4s7 1ntegrin |
| JP2022517610A (ja) | 2019-01-10 | 2022-03-09 | シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド | 複素環化合物塩およびその使用 |
| KR20220109407A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4284947A1 (en) | 2021-01-29 | 2023-12-06 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW6189A1 (en) * | 1988-05-09 | 1990-05-09 | Smithkline Beckman Corp | Anti-aggregatory peptides |
| NZ235563A (en) * | 1989-10-13 | 1993-04-28 | Merck & Co Inc | Fibrinogen receptor antagonist and pharmaceutical composition |
| US5192746A (en) * | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| IL102646A (en) * | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
| JPH08505628A (ja) * | 1993-01-08 | 1996-06-18 | 田辺製薬株式会社 | ペプチド型細胞接着阻害薬 |
| US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| EP0767674A4 (en) * | 1994-06-29 | 1999-06-16 | Texas Biotechnology Corp | METHOD FOR INHIBITING THE BINDING OF INTEGRIN ALPHA 4 BETA 1 TO VCAM-1 OR FIBRONECTIN |
| US5811391A (en) * | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| EP0741948B1 (en) * | 1994-11-02 | 2000-05-10 | Koninklijke Philips Electronics N.V. | Waveform generation |
-
1995
- 1995-12-01 GB GBGB9524630.2A patent/GB9524630D0/en active Pending
- 1995-12-21 HU HU9702198A patent/HUT77120A/hu unknown
- 1995-12-21 WO PCT/GB1995/002992 patent/WO1996020216A1/en not_active Application Discontinuation
- 1995-12-21 JP JP52028596A patent/JP3248584B2/ja not_active Expired - Fee Related
- 1995-12-21 MX MX9704767A patent/MX9704767A/es unknown
- 1995-12-21 NZ NZ297530A patent/NZ297530A/en unknown
- 1995-12-21 SK SK810-97A patent/SK81097A3/sk unknown
- 1995-12-21 PL PL95320995A patent/PL320995A1/xx unknown
- 1995-12-21 BR BR9510284A patent/BR9510284A/pt unknown
- 1995-12-21 US US08/860,248 patent/US6034056A/en not_active Expired - Fee Related
- 1995-12-21 CZ CZ971984A patent/CZ198497A3/cs unknown
- 1995-12-21 CN CN95197007A patent/CN1171118A/zh active Pending
- 1995-12-21 CA CA002204793A patent/CA2204793A1/en not_active Abandoned
- 1995-12-21 AU AU42698/96A patent/AU705717B2/en not_active Ceased
- 1995-12-21 EP EP95941215A patent/EP0800535A1/en not_active Withdrawn
- 1995-12-22 IL IL11651295A patent/IL116512A0/xx unknown
- 1995-12-22 TR TR95/01656A patent/TR199501656A2/xx unknown
-
1997
- 1997-06-23 NO NO972930A patent/NO972930L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9510284A (pt) | 1998-01-06 |
| MX9704767A (es) | 1997-10-31 |
| CA2204793A1 (en) | 1996-07-04 |
| CZ198497A3 (en) | 1997-10-15 |
| NZ297530A (en) | 2000-02-28 |
| NO972930D0 (no) | 1997-06-23 |
| JP3248584B2 (ja) | 2002-01-21 |
| WO1996020216A1 (en) | 1996-07-04 |
| AU705717B2 (en) | 1999-05-27 |
| CN1171118A (zh) | 1998-01-21 |
| US6034056A (en) | 2000-03-07 |
| TR199501656A2 (tr) | 1996-07-21 |
| JPH10508315A (ja) | 1998-08-18 |
| SK81097A3 (en) | 1997-12-10 |
| HUT77120A (hu) | 1998-03-02 |
| EP0800535A1 (en) | 1997-10-15 |
| PL320995A1 (en) | 1997-11-24 |
| AU4269896A (en) | 1996-07-19 |
| GB9524630D0 (en) | 1996-01-31 |
| IL116512A0 (en) | 1996-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO972930L (no) | Fibronectin-adhesjonsinhibitorer | |
| Yaron et al. | Proline-dependent structural and biological properties of peptides and proteins | |
| ATE165836T1 (de) | Peptide als arzneimittel | |
| NZ332778A (en) | Cyclic peptides that are cell adhesion inhibiting compounds that inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen and mucosal addressin cell adhesion molecule-1 | |
| FI102379B1 (fi) | Uretaanisuojattuja aminohappo-N-karboksianhydridejä | |
| Witkop | Chemical Cleavage of Proteins: Selective fragmentations and modifications reveal structure. | |
| Katsoyannis | The synthesis of the insulin chains and their combination to biologically active material | |
| DE69009476T2 (de) | Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen. | |
| ABEL et al. | Structural differences in the hinge region of human gamma A myeloma proteins of different subclasses | |
| ATE205855T1 (de) | Gegen bakterien, mycota und viren wirksame vertebraten proteine und dessen kosmetische zubereitungen | |
| Franciskovich et al. | A systematic evaluation of the inhibition of HIV-1 protease by its C-and N-terminal peptides | |
| KR0154528B1 (ko) | 항응고성 펩티드 | |
| US5192747A (en) | Anticoagulant peptides | |
| ATE140234T1 (de) | Neue inhibitorische peptide | |
| ATE245168T1 (de) | Peptide, die anti-zellanhaftungsaktivität aufweisen | |
| DK0667781T3 (da) | Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier | |
| Moroder et al. | Studies on cytochrome c. Part I. Synthesis of the protected hexadecapeptide (sequence 1–16) of Baker's Yeast iso‐1‐cytochrome c | |
| Ten Kortenaar et al. | Semisynthesis of horse heart cytochrome c analogues from two or three fragments. | |
| WO1993000108A1 (en) | Novel inhibitors of platelet aggregation | |
| Gaudron et al. | NAcSDKP analogues resistant to angiotensin-converting enzyme | |
| Fraenkel-Conrat | The chemistry of proteins and peptides | |
| Nozaki et al. | Synthetic studies on troponin I active site. Preparation of a pentadecapeptide with inhibitory activity toward actomyosin adenosine triphosphatase | |
| ATE85077T1 (de) | Enzym zur alpha-amidierung von c-termini und verfahren zu dessen herstellung. | |
| NO993684L (no) | Peptider som omfatter et T-celle-epitop spesifikt til kollagen-II | |
| ATE46173T1 (de) | Pharmakologisch aktive peptide. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |